Early-stage opportunity Target early-stage breast cancer treatment centers and imaging-guided laser therapy programs in the US and Europe, focusing on facilities that would adopt Novilase as a breast-conserving option to expand clinical trial enrollment and accelerate commercialization.

Regulatory readiness Leverage the FDA Breakthrough Device designation and CE Mark status to position Novilase as a trusted, accelerated path to market for focal destruction of malignant and benign breast tumors, appealing to hospital procurement and oncology committees seeking innovative solutions.

Clinical expansion Drive trials and product adoption through multicenter pivotal studies and European commercialization by engaging academic centers and high-volume breast clinics that can contribute to evidence generation and broadening payer acceptance.

Surgeon collaboration Highlight the image-guided, minimally invasive nature of Novilase to surgical and interventional radiology leaders as a means to reduce retreatments, recovery times, and patient burden, creating compelling value propositions for surgeon-led adoption.

Strategic partnerships Explore partnerships with large medical device distributors and translational research networks, and consider co-marketing with centers earning Frost & Sullivan and other industry recognitions to boost credibility and accelerate channel development.